V Blaha, R Margoczy, I Petrov, A Postadzhiyan, K Raslova, H Rosolova, I Bridges, N N Dhalwani, M Zachlederova, K K Ray
{"title":"Evolocumab在中欧和东欧的LDL-C水平比指南中推荐的高得多的患者中开始使用:观察性HEYMANS研究的结果。","authors":"V Blaha, R Margoczy, I Petrov, A Postadzhiyan, K Raslova, H Rosolova, I Bridges, N N Dhalwani, M Zachlederova, K K Ray","doi":"10.15420/ecr.2023.18.PO19","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":"18 ","pages":"e36"},"PeriodicalIF":3.2000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d9/cb/ecr-18-e36.PMC10316339.pdf","citationCount":"0","resultStr":"{\"title\":\"Evolocumab is initiated in Central and Eastern Europe at Much Higher LDL-C Levels than Recommended in Guidelines: Results from the Observational HEYMANS Study.\",\"authors\":\"V Blaha, R Margoczy, I Petrov, A Postadzhiyan, K Raslova, H Rosolova, I Bridges, N N Dhalwani, M Zachlederova, K K Ray\",\"doi\":\"10.15420/ecr.2023.18.PO19\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":45957,\"journal\":{\"name\":\"European Cardiology Review\",\"volume\":\"18 \",\"pages\":\"e36\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d9/cb/ecr-18-e36.PMC10316339.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Cardiology Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15420/ecr.2023.18.PO19\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Cardiology Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15420/ecr.2023.18.PO19","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
Evolocumab is initiated in Central and Eastern Europe at Much Higher LDL-C Levels than Recommended in Guidelines: Results from the Observational HEYMANS Study.